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Abstract
Introduction: Dendritic cells (DCs) are capable of inducing immunity or tolerance. Previous studies have suggested 
plasmacytoid DCs (pDCs) are pathogenic in systemic lupus erythematosus (SLE). However, the functional 
characteristics of directly isolated peripheral circulating blood pDCs in SLE have not been evaluated previously.
Methods: Peripheral blood pDCs from 62 healthy subjects and 58 SLE patients were treated with apoptotic cells 
derived from polymorphonuclear cells (PMNs). Antigen loaded or unloaded pDCs were then co-cultured with 
autologous or allogenous T cells. Changes in T cell proliferation, cell surface CD25 expression, intracellular Foxp3 
expression and cytokine production were evaluated. pDCs that had captured apoptotic PMNs (pDCs + apoPMNs were 
also studied for their cytokine production (interferon (IFN)-alpha, interleukin (IL)-6, IL-10, IL-18) and toll like receptor 
(TLR) expression.
Results: Circulating pDCs from SLE patients had an increased ability to stimulate T cells when compared with control 
pDCs. Using allogenous T cells as responder cells, SLE pDCs induced T cell proliferation even in the absence of 
apoptotic PMNs. In addition, healthy pDCs + apoPMNs induced suppressive T regulatory cell features with increased 
Foxp3 expression in CD4 + CD25 + cells while SLE pDCs + apoPMNs did not. There were differences in the cytokine 
profile of pDCs that had captured apoptotic PMNs between healthy subjects and patients with SLE. Healthy pDCs + 
apoPMNs showed decreased production of IL-6 but no significant changes in IL-10 and IL-18. These pDCs + apoPMNs 
also showed increased mRNA transcription of TLR9. On the other hand, while SLE pDCs + apoPMNs also had decreased 
IL-6, there was decreased IL-18 mRNA expression and persistent IL-10 protein synthesis. In addition, SLE pDCs lacked 
TLR9 recruitment.
Conclusions: We have demonstrated that peripheral circulating pDCs in patients with SLE were functionally abnormal. 
They lacked TLR9 expression, were less capable of inducing regulatory T cell differentiation and had persistent IL-10 
mRNA expression following the capture of apoptotic PMNs. We suggest circulating pDCs may be pathogenically 
relevant in SLE.
Introduction
Dendritic cells (DCs) are professional antigen presenting
cells (APCs) with important immunoregulatory func-
tions. They are the only cells that can stimulate naïve T
cells [1]. Commonly, DCs circulate in peripheral tissues,
capture pathogens or dying cells, and present antigens to
T cells. T cells then proliferate and differentiate into Th1
(cell immunity), Th2 (humoral immunity) or T regulatory
(Treg) (suppressive) cells resulting in the induction of
immunity or tolerance [2]. Recent studies have shown
that cytokines produced by DCs contribute to the induc-
tion of T cell differentiation [1]. For example, interleukin
(IL)-6 primes CD4+T cells to differentiate into Th2 cells
[3] and suppresses the activity of Treg cells [4]. IL-10
inhibits Th1 but induces Th2 responses [5]. IL-18, previ-
ously known as IFN-γ-inducing factor, interacts with IL-
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tion into interferon (IFN)-γ producing Th1 cells [6].
Considering the role of DCs in the induction of immu-
nity or tolerance in health, changes in DC function in
autoimmune diseases such as systemic lupus erythemato-
sus (SLE) which is characterized by loss of tolerance to
self antigens have been studied intensively. Actually, DC
functional abnormalities in SLE have been reported pre-
viously, the main progress of which is on the pathogenic
role of plasmacytoid DCs (pDCs) in this condition [7].
Though the precise role of pDCs in the immune system is
still unclear, these cells have been shown to polarize T
cells through its high production of IFN-α [2] , which is
generally considered to be the central cytokine that con-
tributes to SLE development [8]. However, it is puzzling
that some previous studies have reported diminished
IFN-α production and T cell-stimulatory capacity by
cytokine-induced pDCs in SLE [9]. Further, high serum
levels of IFN-α are only found in some but not all SLE
patients [10]. The role of pDCs in SLE requires further
clarification.
Apoptotic cells are the primary source of autoantigens
in SLE [11,12]. Nucleic-acid containing macromolecules
which comprise the majority of autoantigens in SLE have
been detected on the surface of apoptotic bodies [13].
The hypothesis is that in the process of apoptosis, nuclear
antigens are cleaved into DNA fragments, revealing pre-
viously cryptic epitopes or neoepitopes to activate the
immune system [12]. Supportive evidence comes from
studies which showed DNA fragments isolated from sera
of SLE patients stimulated mononuclear cell prolifera-
tion, and that these DNA fragments were of the same size
as internucleosomal digested DNA from apoptotic cells
[14].
Recently, an animal study has shown apoptotic cell-
pulsed bone marrow-derived DCs (AC-BMDCs) could
induce the proliferation of self reactive T-cells resulting in
tolerance break down and initiation of autoimmune
responses in normal mice [15]. However, until now no
direct studies have been carried out in human SLE evalu-
ating the function of peripheral blood pDCs and their
interactions with immune cells following loading with
apoptotic cells. In this study, we carried out experiments
to examine the characteristics and functions of freshly
isolated circulating pDCs from healthy and SLE subjects
in the absence or presence of apoptotic cells. We hypoth-
esize that peripheral circulating pDCs are functionally
abnormal in SLE.
Materials and methods
Subjects
Patients who fulfilled the American College of Rheuma-
tology criteria for SLE [16] were studied. There were 50
females and 8 males, with their age ranging from 21 to 62
(41.76 ± 9.15) years and disease duration from 1 to 28
(10.58 ± 7.16) years. Disease activity was assessed using
the SLE disease activity index (SLEDAI) [17]. Active dis-
ease was defined as SLEDAI ≥ 5 (n = 26). Thirty-two
patients had inactive disease (SLEDAI < 5). Sixty-two sex-
and age-matched healthy volunteers were recruited from
the Red Cross Blood Transfusion Section. The study was
approved by the Hong Kong West Cluster Institutional
Review Board for medical ethics. All subjects provided a
written informed consent.
An overview of the experimental design
(1) Circulating blood pDCs were isolated and cultured
with or without apoptotic cells; (2) Antigen loaded or
unloaded pDCs were then co-cultured with autologous or
allogenous T cells. The same control T cells were used as
responder cells in all allogenic proliferation assays.
Changes in T cell proliferation, cell surface marker CD25
expression, CD4+CD25+ Foxp3+ expression and cytokine
production were evaluated; and (3) functional changes of
pDCs after interaction with apoptotic cells were evalu-
ated by detection of cytokine production and toll-like
receptor (TLR) expression.
Blood collection and cell isolation
A total of 100 mls of sodium citrate anti-coagulated blood
were collected between 9:00 and 11:00 AM. Peripheral
blood mononuclear cells (PBMCs) were freshly isolated
by Ficoll density gradient centrifugation. pDCs and T
cells from PBMCs were magnetically sorted with the
human BDCA-4 DC and pan T isolation kits respectively
according to the manufacturer's description (Miltenyi
Biotec, Berqisch Gladbach, Germany). Briefly, pDCs were
positively selected using anti-BDCA-4 conjugated beads
[18]. T cells were negatively isolated using magnetic
beads conjugated with various surface antigen antibodies
(anti-CD14, anti-CD16, anti-CD19, anti-CD36, anti-
CD56, anti-CD123) to remove non-T cells. The purity of
pDCs and T cells was approximately 90% and approxi-
mately 99%, respectively.
After isolating PBMCs from the whole blood, dextran
sedimentation was applied to separate polymorphonu-
clear cells (PMNs, neutrophils) from red blood cells
(RBCs). The remaining RBCs were lyzed with ammonium
chloride (BD, CA) and removed by washing with saline.
Purified PMNs were then resuspended with complete
RPMI 1640 medium at a concentration of 5 × 106 cells/ml.
PMNs were given 120 mJ/ml ultraviolet (UV) irradiation
using the CL-100 Ultraviolet Crosslinker (Upland, CA,
USA) to induce apoptosis. Sixteen hours after UV irradia-
tion, the rate of apoptosis on PMNs reached around 60%
to 90% and was confirmed by microscopic examination of
cytocentrifuge stained with May-Giemsa, and flow cyto-
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staining (double positive cells).
Interaction of dendritic cells with apoptotic cells
pDCs were incubated with apoptotic PMNs for four
hours. pDCs that had captured apoptotic PMNs (pDCs +
apoPMNs) were confirmed by flow cytometry detection
of surface PE-Cy5 CD123 (for pDC) and 5-(and 6)-car-
boxytetramethylrhodamine succinimidyl ester (for
PMNs) double positive stained cells, the percentage of
which was around 15%. pDCs or pDCs + apoPMNs were
then treated with mitomycin C, which has the ability to
inhibit proliferation without affecting the viability of the
feeder cells. The cell cultures were subsequently washed
with phosphate buffer solution (0.5% BSA) to remove
mytomycin C and apoptotic PMNs, for T cell interaction
experiments or for evaluation of cytokine and TLR
expression.
Mixed leukocyte reaction (MLR)
T cell proliferation and differentiation induced by pDCs
were evaluated by MLR. In brief, pDCs (1.0 × 104) or
pDCs that had interacted with apoptotic PMNs for four
hours (pDC:PMN ratios = 1:1, 1:5, and 1:10) were used to
stimulate autologous or allogenous responder T cells (1.0
× 105). After five days of culture in a 96-well round-bot-
tom culture plates with 200 μl of complete RPMI 1640
culture medium, the culture supernatants were collected
for the detection of cytokines produced by T cells, and
fresh medium was added back. Following that, 0.5 μCi
tritiated thymidine (Radiochemical Centre, Amersham,
Little Chalfont, Buckinghamshire, UK) was added per
well for 16 hours. T cell proliferation was measured by
detection of the incorporation of (3H)-thymidine. Cells
were harvested with a Packard FilterMate™ Universal
Harvester (Downers Grove, IL, USA) and read with a
TopCount™ NXT Microplate Scintillation Counter (Per-
kin Elmer, Boston, MA, USA). After the initial experi-
ments, we found the 1:10 pDC:PMN ratio resulted in
maximum T cell stimulation. This ratio was used in later
experiments.
Flow cytometry
The purity of pDCs and T cells was confirmed by surface
immunofluorescence staining and flow cytometry analy-
sis. pDCs were defined as BDCA-2+CD123+lin- cells [19]
and its purification was above 90% [18]. Comparable lev-
els of surface markers expression including MHC-II
CD86 CD83 and CCR7 were found in pDCs from both
SLE and healthy [18]. T cells were defined as CD3+ cells
and its purification is about 99% (data not shown).
Changes in surface CD25 expression of T cells stimulated
by pDCs were measured by percentage of CD4+CD25+
cells per CD4+ T cells and compared with that of unstim-
ulated T cells. To further investigate whether the
CD4+CD25+ T cells were Treg cells or not, intracellular
immunofluorescence staining of Foxp3 was carried out
according to the manufacturer's description (eBioscience,
San Diego, CA, USA). Appropriate isotype-matched con-
trol Ig was used as negative controls for each analysis.
Flow cytometric analysis was performed within 24 hours,
on a FACSCalibur flow cytometry using Cellquest soft-
ware.
ELISA
Cytokines produced by T cells after interaction with
pDCs or pDCs + apoPMNs were measured using OptE-
IATM ELISA (BD Biosciences Pharmingen, San Diego,
CA, USA). Supernatants in the MLR system were col-
lected after five days culture and frozen at -70°C for sub-
sequent cytokine detection. These cytokines included
IFN-γ, tumor necrosis factor (TNF)-α and IL-2 (Th1
cytokines); IL-4 and IL-6 (Th2 cytokines); and IL-10 and
transfer growth factor (TGF)β (Treg cytokines) [2].
Changes in cytokine production by pDCs or pDCs +
apoPMNs were evaluated also using ELISA. Supernatants
from the pDC culture system were collected after 24
hours' culture and frozen at -70°C for subsequent detec-
tion of IFN-α, IL-6, IL-10, IL-12, TNF-α levels. Human
IFN-α ELISA kit was obtained from PBL Biomedical Lab-
oratory (Piscataway, NJ, USA). ELISA results were read
using MQX200 FCC Compliance (BID-TEK Instruments,
Inc., Sacramento, CA, USA).
Real time polymerase chair reaction (PCR)
Semi-quantitative real time PCR was applied to detect
changes in cytokine or TLR mRNA gene expression in
pDCs after interaction with apoptotic cells for four hours.
pDCs without interaction with apoptotic PMNs and
PMNs alone were used as controls. Total RNA from the
culture system was isolated through PurelinkTM Micro-
to-Midi Total RNA Purification System (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer's
description. First-strand complementary DNA was sub-
sequently synthesized using the SuperScriptTM First-
Stand Synthesis System (Invitrogen). For real-time PCR
detection of target and housekeeping gene expression,
the fluorescent TaqMan 5'-nuclease assay was performed
using 2× TaqMan Universal PCR Master Mix and Taq-
Man Gene Expression assays (two unlabeled primers and
one 6-FAM or VIC dye -labeled TaqMan MGB probe) for
IL-6 (Hs00174131-ml), IL-10 (Hs00174086-ml), IL-18
(Hs00155517-ml), IFN-α1 (Hs00256882-sl), TLR-4
(Hs00152939-ml), TLR-7 (Hs00152971-ml), TLR-9
(Hs00370913-sl) and 18S (Hs999999901-sl) (Applied Bio-
systems, Foster City, CA, USA). The reaction was per-
formed in triplicate on an ABI 7000 Sequence Detector
(Applied Biosystems) with a standard run. The expression
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housekeeping genes 18S. The fold change in the pDC tar-
get gene expression was adjusted to that of 0 hour, repre-
sented as the 2-ΔΔCt, where ΔΔCt = (Ct.target -
Ct.18S)Time.x - (Ct.target - Ct.18S)Time.0h.
Statistical analysis
As this was the first study on human peripheral circulat-
ing pDCs, the data were first tested for normality before
statistical analysis to detect group differences was carried
out. Normally distributed data are expressed as mean ±
SD while non-normally distributed data as median (inter-
quartile range). For comparison across different groups, a
two-factor analysis of variance (ANOVA) was used for
normally distributed data. In case the ANOVA indicated
differences across groups (P < 0.10), a pair-wise Student's
t-test was used to evaluate the explicit P-values. Similarly,
the Kruskal-Wallis test was used to compare across dif-
ferent groups of non-normally distributed data. If differ-
ences were indicated across groups, a Wilcoxon's rank
sum test for two samples was used to evaluate the explicit
P-values.
Results
T cell proliferation stimulated by pDCs or pDCs + apoPMNs
Autologous MLR T cell proliferation
pDCs from healthy donors (n = 36) did not induce autolo-
gous T cell proliferation whether they were fed with
apoptotic cells or not (Figure 1a). Similarly, SLE (n = 30)
pDCs did not stimulate autologous T cell proliferation,
irrespective of the overall SLE disease activity (Figure 1a).
Allogenous MLR T cell proliferation
In the allogenous MLR system, only pDCs + apoPMNs
from healthy subjects (n = 36) induced allogenous T cell
proliferation while both pDCs and pDCs + apoPMNs
from SLE patients (n = 30) were able to induce T cell pro-
liferation (Figure 1b). As pDCs have a high rate of apopto-
sis themselves [20] (approximately 40%, unpublished
data), pDCs alone cultures may be regarded as a system of
low level self-antigen presentation. These results suggest
SLE pDCs have a higher ability to stimulate T cells than
controls. This was observed irrespective of the patients'
disease activity.
CD25 and Foxp3 expression on CD4+ T cells
In the autologous MLR system, neither healthy nor SLE
pDCs or pDCs + apoPMNs increased CD25 expression
on CD4+ T cells (Figure 2a). In the allogenous MLR sys-
tem, both healthy and SLE pDCs + apoPMNs induced
CD25 expression on CD4+ T cells (Figure 2b). Consistent
with the proliferation assay results, SLE pDCs alone
increased CD25 expression on allogenous CD4+ T cells
(Figure 2b), indicating that SLE pDCs had a higher ability
to stimulate CD25 expression on allogenous CD4+ T cells.
To evaluate whether the CD25+CD4+ T cells may repre-
sent either active effector T cells or immunosuppressive
Treg cells [21], intracellular staining and flow cytometry
detection of Foxp3, Treg cell signatory, [22] were carried
out. The percentage of CD4+CD25+ T cells that were
Foxp3+ was evaluated. Neither healthy nor SLE pDCs
changed the expression of Foxp3 in autologous
Figure 1 T cell proliferation following stimulation with pDCs 
alone or pDCs + apoPMNs in the MLR systems. (a) In the autolo-
gous MLR system: pDCs from healthy donors (n = 36) did not induce T 
cell proliferation, regardless of loading with apoptotic PMNs or not. 
The same phenomenon was also found in SLE patients (n = 30; 12 with 
active disease and 18 with inactive disease), irrespective of disease ac-
tivity status. (b) In the allogenous MLR system: In healthy donors (n = 
36), only pDCs + apoPMNs induced allogenous T cell proliferation. 
With SLE pDCs, both pDCs alone and pDCs + apoPMNs induced allog-
enous T cell proliferation, suggesting a higher ability of SLE pDCs to 
stimulate allogenous T cells. Values are expressed in Median (inter-
quartile range, range). auto-T: autologous T cells, allo-T: allogenous T 
cells, pDCs + apoPMNs: pDCs that had been loaded with apoptotic 
polymorphonuclear cells. HD, healthy donors; aSLE, active SLE; iSLE, in-
active SLE
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CD4+CD25+ T cells, however, healthy pDCs + apoPMNs
increased the expression of Foxp3 (Figure 2d, P < 0.05)
while no significant changes were found with either SLE
pDCs alone or pDCs + apoPMNs. These results suggest
that healthy but not SLE pDCs induced the development
of suppressive Treg cells.
T cell cytokine production
Neither healthy nor SLE pDCs or pDCs + apoPMNs
induced autologous T cells to produce Th1 (Figure 3a1,
Figure 3b1) or Th2 related cytokines (data not shown). In
the allogenous MLR system, both healthy and SLE pDCs
+ apoPMNs induced Th1 cell related cytokines including
IFNγand IL-2 (Figure 3a2, 3b2).
Both autologous and allogenous T cells that were co-
cultured with healthy pDCs produced a small amount of
Treg cell related TGFβ (Figure 3c) but the changes were
not statistically significant.
Changes in the functional characteristics of pDCs + 
apoPMNs
pDC cytokine production
Following incubation with apoptotic cells for four hours,
both healthy and SLE pDCs showed a slight increase in
the expression of IFNα mRNA but it did not reach statis-
tical significance (Figure 4a1). Both healthy and SLE
pDCs + apoPMNs had decreased mRNA expression of
IL-6 (Figure 4a2). There were no significant changes in
the IL-10 mRNA expression of both healthy and SLE
pDCs + apoPMNs (Figure 4a3). IL-18 mRNA expression
in normal pDCs + apoPMNs did not change significantly
but SLE pDCs - apoPMNs had decreased IL-18 mRNA
expression (Figure 4a4).
Results of the ELISA of cytokines in supernatants of
pDCs + apoPMNs cultures were in accordance with
mRNA expression findings above. There were no changes
in the level of IFNα from healthy and SLE pDCs + apoP-
MNs (Figure 4b1). IL-6 production by healthy and SLE
pDCs + apoPMNs was both decreased (Figure 4b2).
Interestingly, however, IL-10 production by healthy pDCs
+ apoPMNs was reduced but remained unchanged in SLE
pDCs + apoPMNs (Figure 4b3).
pDC TLR expression
TLR9 mRNA expression in healthy pDCs + apoPMNs
was found to be increased (Figure 5c) (P < 0.05). This was
not observed with SLE pDCs + apoPMNs. No significant
differences in the changes in TLR7 and TLR4 mRNA
expression in between healthy and SLE pDCs + apoPMNs
were detected (Figure 5a, b).
Discussion
Previous reports have shown pDCs induce immune toler-
ance after phagocyting apoptotic cells [23]. However,
Figure 2 CD4 + T cell CD25 and Foxp3 expression following incu-
bation with pDCs or pDCs + apoPMNs in MLR systems. (a) Autolo-
gous MLR system T cell CD25 expression: No changes were detected 
on CD4 + T cells from either healthy subjects (n = 36) or patients with 
SLE (n = 30; 12 with active disease and 18 with inactive disease) follow-
ing incubation with pDCs alone or pDCs + apoPMNs. Values are ex-
pressed in Median (interquartile range, range). (b) Allogenous MLR 
system T cell CD25 expression: CD25 expression was increased follow-
ing incubation with healthy pDCs + apoPMNs (n = 36) but not pDCs 
alone, whereas a significant increase was seen following incubation 
with both SLE pDCs alone and pDCs + apoPMNs (n = 30). Values are ex-
pressed in Median (interquartile range, range). (c) Autologous MLR sys-
tem CD4 + CD25 + T cell intracellular staining of Foxp3: No changes 
were detected following incubation with either pDCs alone or pDCs + 
poPMNs from healthy subjects (n = 6) and patients with SLE (n = 6). Val-
ues are expressed in Mean ± SEM. (d) Allogenous MLR system CD4 + 
CD25 + T cell intracellular staining of Foxp3: pDCs + apoPMNs from 
healthy donors increased the expression of Foxp3 on allogenous CD4 
+ CD25 + T cells (n = 8, P < 0.05), but no significant changes were seen 
with SLE pDCs alone or pDCs + apoPMNs (n = 8). Values are expressed 
in Mean ± SEM. auto-T: autologous T cells, allo-T: allogenous T cells, 
pDCs + apoPMNs: pDCs that had been loaded with apoptotic poly-
morphonuclear cells. HD, healthy donors; aSLE, active SLE; iSLE, inac-
tive SLE.
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Figure 3 T cell production of IFNγ, IL-2 and TGFβ following incubation with pDCs alone and pDCs + apoPMNs. (a1) and (b1) Autologous T 
cells that had been incubated with either healthy donor (n = 30) or SLE (n = 30) pDCs alone or pDCs + apoPMNs did not produce Th1 related cytokines 
IFNγ and IL-2. (a2) and (b2) Allogeneous T cells that had been incubated with either HD (n = 30) or SLE (n = 30) pDCs + apoPMNs produced IFNγ and 
IL-2. (c) Autologous and allogeneous T cells that had been incubated with either HD (n = 30) pDCs alone or pDCs + apoPMNs produced low levels of 
Treg related TGFβ though the difference did not reach statistical significance. Values are expressed in Median (interquartile range, range). auto-T, au-
tologous T cells; allo-T, allogenous T cells; pDCs + apoPMNs, pDCs that had been loaded with apoptotic polymorphonuclear cells; HD, healthy donors.
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Figure 4 Changes in mRNA expression and protein levels of cytokines in HD and SLE pDCs + apoPMNs. (a) Changes in IFNα, IL-6, IL-10 and IL-
18 mRNA expression in HD (n = 7) and SLE (n = 7) pDCs + apoPMNs. IFNα mRNA expression (A1) appeared increased in both HD and SLE pDCs + 
apoPMNs but the changes did not reach statistical significance. IL-6 (A2) mRNA expression was significantly decreased in both HD and SLE pDCs + 
apoPMNs. IL-10 mRNA expression (A3) did not change in both HD pDCs + apoPMNs. IL-18 mRNA expression (A4) did not change in HD pDCs + apo-
PMNs but was significantly decreased in SLE pDCs + apoPMNs. (b) protein levels of IFNα, IL-6 and IL-10 in the supernatants of cultured HD (n = 8) and 
SLE (n = 8) pDCs + apoPMNs (B1, B2 and B3). Results were compared with cultured pDCs alone. B1) No significant differences in the levels of IFNα in 
the culture supernatants of both HD and SLE pDCs + apoPMNs were detected. B2) Levels of IL-6 were significantly decreased in the culture superna-
tants of both HD and SLE pDCs + apoPMNs. B3) Levels of IL-10 in the culture supernatants of HD pDCs + apoPMNs were significantly decreased while 
no significant changes were found in that of SLE pDCs + apoPMNs. Values are expressed in Median (interquartile range, range). pDCs + apoPMNs, 
pDCs that had been loaded with apoptotic polymorphonuclear cells; HD, healthy donors; IFNα, Interferon α; IL, Interleukin.
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ber of apoptotic cells in the circulating blood are associ-
ated with autoimmunity [10,24]. Thus, we designed the
current series of experiments to investigate the capacity
of apoptotic cell loaded pDCs in stimulating T cells. To
our knowledge, this is the first study which evaluated the
effects of directly isolated peripheral pDCs on T cells in
healthy subjects and patients with SLE. Our results show
that healthy pDCs + apoPMNs did not induce autologous
T cell proliferation (Figure 1a). This lack of ability of
pDCs to stimulate self T cells even when they encoun-
tered apoptotic cells suggests that pDCs may play a toler-
ance role in immunity in health. Indeed, previous animal
studies have also suggested a tolerance role of pDCs [25].
In humans, pDCs have been found to elicit antigen-spe-
cific anergy in CD4+ T cell lines [26]. Furthermore,
monocty-derived DCs were reported to be poor stimula-
tors of T cells [25]. Our previous study on human circu-
lating pDCs also suggested a low stimulatory capacity of
pDCs as evidenced by their low level of co-stimulatory
surface molecule expression [18].
We also investigated the ability of pDCs to stimulate
allogenous T cells as an assessment of the antigen-pre-
senting capability of DCs [27]. We found that healthy
pDCs + apoPMNs induced only a very low level of alloge-
nous T cell proliferation (Figure 1b) while SLE pDCs were
more capable of inducing allogenous T cell proliferation
(Figure 1b). Some previous studies have shown the oppo-
Figure 5 TLR4, TLR7 and TLR9 expression on HD and SLE pDCs + apoPMNs. HD (n = 5) pDCs + apoPMNs showed a significant increase in the 
expression of TLR9 mRNA (c) while SLE (n = 5) pDCs + apoPMNs did not. No significant changes in TLR4 (a) and TLR7 (b) expression were found in 
either HD or SLE pDCs + apoPMNs. Values are expressed in Median (interquartile range, range). pDCs + apoPMNs, pDCs that had been loaded with 
apoptotic polymorphonuclear cells; HD, healthy donors.
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patients have been shown to have diminished T cell stim-
ulatory capacity [28], or SLE peripheral DCs had reduced
capacity to induce concanavalin A (Con A)-stimulated T
cell proliferation [29]. However, these studies did not use
purified DCs and their functions may be altered by other
cells that were present in the assay.
In accordance with the proliferation results above,
allogenous CD4+ T cells that were co-cultured with either
healthy or SLE pDCs + apoPMNs were found to have an
increased expression of CD25 (Figure 2b). CD4+CD25+ T
cells may consist of either specific Th or Treg cell subsets
[21]. As Foxp3 is now regarded as the specific signature of
Treg cells [22], we evaluated the expression of Foxp3+ in
allogenous CD4+CD25+ T cells induced by pDCs, only
healthy pDCs + apoPMNs were found to have increased
Foxp3 expression (Figure 2d), indicating the development
of Treg cells. This is consistent with a recent mouse
model which showed that murine pDCs that had
acquired alloantigens from allografts during transplant
mediated antigen-specific Treg cell development and
allograft tolerance [30]. Studies on human pDCs have
also revealed that CpG-oligodeoxynucleotides (ODN)
stimulated circulating pDCs were able to induce Treg cell
expansion [31]. Treg cells maintain peripheral tolerance
by suppressing the activation and population expansion
of self-reactive T cells [32].
Contrary to healthy pDCs - apoPMNs, SLE pDCs +
apoPMNs did not induce Foxp3+ expression in
CD4+CD25+T cells (Figure 2d). The important role of
Foxp3+CD4+CD25+ Treg cells in immune homeostasis is
that it controls autoimmunity throughout life. In animal
models, Treg cell removal by neonatal thymectomy
causes the spontaneous development of various organ-
specific autoimmune diseases [33,34]. Therefore, the lack
of capacity of SLE pDCs to induce Treg development may
contribute to the break down of immune tolerance and
the development of autoimmunity. Indeed, SLE patients
have been found to have significantly lower numbers of
CD4+CD25+ T cells than normal persons [35]. In addi-
tion, a decreased suppressive function of CD4+CD25high
Treg cells with reduced level of Foxp3 mRNA and protein
expression has also been found in active SLE [36].
Recently, a study has shown that APCs from SLE patients
were responsible for decreased Treg cell activity though
the authors had used non-T cells as APCs [37].
An important feature that differentiates the various
subsets of T cells is the characteristic profile of cytokines
produced by these cells [38,39]. Our results showed that
both healthy and SLE pDCs + apoPMNs stimulated T
cells produced Th1 related IFNγ and IL-2 (Figure 3a2,
3b2). Only healthy pDCs + apoPMNs stimulated T cells
produced Treg2 cell-related TGFβ (Figure 3c) though the
difference did not reach statistical significance. However,
this latter finding provides further support of the notion
that healthy pDCs + apoPMNs induce tolerogenic Treg
cell expansion while SLE pDCs + apoPMNs do not.
Functional changes of pDCs + apoPMNs including
cytokine production and TLR expression [40] were stud-
ied to delineate the probable mechanisms of these pDCs'
effects on T cells. We found that circulating healthy pDCs
+ apoPMNs had decreased mRNA expression and pro-
tein levels of IL-6 (Figure 4a2) and protein levels of IL-10
(Figure 4B3). SLE pDCs + apoPMNs were also found to
have decreased mRNA expression and protein levels of
IL-6 (Figure 4a2). However, we also noted a decrease in
IL-18 mRNA expression (Figure 4a4) and no significant
changes in IL-10 protein levels in the supernatant of the
SLE pDCs + apoPMNs cultures. These findings are inter-
esting as DC IL-18 is involved in the induction of Th1
response and IL-10 induces Th2 response during interac-
tions with T-cells. Our findings are in accordance with
the notion that SLE is characterized by a Th1/Th2 imbal-
ance toward Th2 dominance.
TLRs play an important role in the presentation of anti-
gens derived from apoptotic cells by DCs [40-43]. In our
study, we found that healthy pDCs + apoPMNs increased
their expression of TLR9 mRNA (Figure 5c) and TLR4
mRNA (Figure 5a) while TLR7 (Figure 5b) mRNA expres-
sion remained unchanged (Figure 5a). A previous study
has reported that human pDCs activated by the TLR9
ligand CpG-ODN could induce CD4+CD25+ Treg cells
[31]. With SLE pDCs + apoPMNs, however, no increase
in TLR9 mRNA expression was found (Figure 5c). This is
consistent with data presented in a previous study which
found that the expression of TLR9 on SLE pDCs stimu-
lated by CpG ODN decreased rapidly [44]. We hypothe-
size that this difference in TLR9 recruitment between
SLE and healthy pDCs may partly contribute to the lack
of induction of Treg cells development in SLE, and this
may further contribute to the tolerance break-down and
autoimmune disease development.
A limitation of this study is that most of the patients
were receiving some form of treatment including immu-
nosuppressive agents. It is therefore not possible to con-
firm whether the pDC changes were a result of the
underlying disease or that of the various lupus medica-
tions. It should, however, be noted that differential
changes were seen in patients with different levels of
lupus disease activity. In general, the more active the dis-
ease was, the more adverse pDC changes were noted. It is
therefore tempting to suggest that our findings reflect the
true role of pDCs in lupus disease pathogenesis. Future
studies should aim to recruit treatment of naïve or newly
diagnosed patients with SLE. However, this will have to
involve the collaboration of multiple lupus research units.
It has taken the authors over two years to recruit 58 suit-
Jin et al. Arthritis Research & Therapy 2010, 12:R137
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Page 10 of 11able patients from a cohort of over 500 patients for the
purpose of this study.
Conclusions
Our study has provided further insights into the role of
pDCs in SLE. In patients with SLE, the capacity of circu-
lating pDCs to stimulate T cells was increased while their
ability to induce Treg cell development was decreased.
These may be the results of decreased IL-18 and
increased IL-10 transcription which may prime Th2
response, and low expression of TLR9 following pDCs'
interaction with apoptotic cells.
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